Telix Urology Innovation Showcase

June 21, 2023, at The Yale Club, New York City

Melbourne (Australia) and Indianapolis (United States) | 21 June 2023

Telix today provides an outline agenda for the Company’s briefing session for shareholders to be held on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am EDT (10.30pm AEST) and via live webcast.[1] The briefing session will provide an opportunity for shareholders to hear from the Company in relation to its recent market disclosures[2] and will focus on:

  • Telix’s vision for the field of urology
  • The commercialisation of Telix’s lead product Illuccix® for prostate cancer imaging
  • The Company’s pipeline in urologic oncology, including current clinical activity.

The briefing will also feature key opinion leaders’ perspectives on the clinical utility of the Company’s investigational products TLX250-CDx for renal cancer imaging and TLX591 for prostate cancer therapy.  

Briefing session agenda:

  • Dr. Christian Behrenbruch (CEO and Group Managing Director) will provide an overview of the Company’s growth strategy in urologic oncology
  • Kevin Richardson (CEO Telix Americas) will present on how Telix has built its commercial organisation to meet the needs of the urologic customer base
  • Dr. Colin Hayward (Chief Medical Officer) will discuss published clinical and scientific evidence supporting the expanded utility of prostate-specific membrane antigen (PSMA) imaging and the scientific rationale for the Company’s carbonic anhydrase (CAIX) program in renal cancer therapy and current clinical programs
  • Brian Shuch, MD, Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA will detail the results of the Company’s Phase III ZIRCON study and a clinician’s perspective on the potential utility of the imaging candidate
  • Scott T. Tagawa, MD, MS, FACP, Professor of Medicine and Urology will discuss clinical and scientific insights into the Company’s TLX591 program for prostate cancer therapy.  

Shareholders wishing to attend this briefing session in person are required to register their attendance through this link.

The briefing session will also be broadcast live via webcast for shareholders who cannot attend in person.  Please register at this link for the live webcast.

A recording of the event will also be made available on the Company’s website.

[1] Telix media release 25 May 2023.

[2] Telix ASX disclosures 17 April, 27 April, 1 May, 24 May and 19 June 2023.